252 related articles for article (PubMed ID: 17199716)
1. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.
Schreiber SA; Haak T
Diabetes Obes Metab; 2007 Jan; 9(1):31-8. PubMed ID: 17199716
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice.
Schreiber SA; Ferlinz K; Haak T
Diabetes Technol Ther; 2008 Apr; 10(2):121-7. PubMed ID: 18260775
[TBL] [Abstract][Full Text] [Related]
3. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
Davies M; Lavalle-González F; Storms F; Gomis R;
Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
[TBL] [Abstract][Full Text] [Related]
4. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
5. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.
Hammer H; Klinge A
Int J Clin Pract; 2007 Dec; 61(12):2009-18. PubMed ID: 17997807
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
8. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
9. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
13. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
15. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
17. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study.
Yang W; Lv X; Li Q; Jia W; Tian H
Curr Med Res Opin; 2012 Apr; 28(4):533-41. PubMed ID: 22449098
[TBL] [Abstract][Full Text] [Related]
18. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
20. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
Raskin P; Allen E; Hollander P; Lewin A; Gabbay RA; Hu P; Bode B; Garber A;
Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
